<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906345</url>
  </required_header>
  <id_info>
    <org_study_id>A 2016-0144</org_study_id>
    <nct_id>NCT02906345</nct_id>
  </id_info>
  <brief_title>TPE in Septic Patients and Influence on Organ Failure</brief_title>
  <acronym>TPEMOF</acronym>
  <official_title>&quot;Analyses on the Effectiveness and Technical Optimization of Therapeutic Plasma Exchange for Patients With Septic Shock, With Special Emphasis on Influencing the Kidney, Liver and Nervous System Through the Extracorporeal Therapy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic plasma exchange (TPE) should used for patients with septic shock in a controlled,
      prospective study focusing on the organ functions of the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic plasma exchange (TPE) should used for patients with septic shock in a controlled,
      prospective study.

      Investigators will study three groups:

        1. untreated control group;

        2. TPE group, plasma separation carried out by filtration;

        3. TPE group, plasma separation carried out by centrifugation.

      All treated patients should treated two (minimal) to five times by TPE, depending on the need
      of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be
      exchange. Fluid resuscitation will be done with fresh frozen plasma. The study will focusing
      on the organ functions of the patients, especially liver-, kidney- and nervous function and
      also displayed in the SOFA score on study days 3 and 7.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA score ≥ 2 Punkte</measure>
    <time_frame>day 3</time_frame>
    <description>SOFA: Sepsis-related Organ Failure Assessment score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SOFA score ≥ 2 Punkte</measure>
    <time_frame>day 7</time_frame>
    <description>SOFA: Sepsis-related Organ Failure Assessment score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day survival</measure>
    <time_frame>day 28</time_frame>
    <description>Observation time 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital survival</measure>
    <time_frame>1 year</time_frame>
    <description>Leave the patients the hospital?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of thrombocytes (DIC)</measure>
    <time_frame>days 1-7, 14, 21, 28</time_frame>
    <description>values of thrombocytes, screening for DIC</description>
  </other_outcome>
  <other_outcome>
    <measure>Haptoglobulin values</measure>
    <time_frame>days 1-7, 14, 21, 28</time_frame>
    <description>values haptoglobulin, screening for hemolysis</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Organ Failure</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPE-Filtration Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPE-Centrifugation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic Plasma Exchange (TPE)</intervention_name>
    <description>All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.</description>
    <arm_group_label>TPE-Filtration Group</arm_group_label>
    <arm_group_label>TPE-Centrifugation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock, beginning of shock &lt; 24 hours

        Exclusion Criteria:

          -  Participation in an another clinical trial within the last 30 days

          -  Participation in this study at an earlier date

          -  Simultaneous participation in another clinical trial

          -  Pregnancy

          -  Unpredictable Bleeding (over 2 erythrocyte concentrates daily)

          -  Polyneuropathy (known before the beginning of sepsis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Sauer, MD</last_name>
    <phone>493814946409</phone>
    <email>martin.sauer@uni-rostock.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intensive Care Units PIT 1+2, University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Sauer, PD Dr.</last_name>
      <phone>49 381 4946434</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Dr. Martin Sauer, MD</investigator_full_name>
    <investigator_title>PD Dr. med. habil.; MD</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Fresh frozen plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

